DSR6434

DSR6434 is a **synthetic small molecule agonist** targeting *Toll-like receptor 7 (TLR7)*, designed to activate components of the innate and adaptive immune system. It activates several immune effector cells and induces cytokine production (including IFN-α, IL-6, IL-8, and TNF) upon administration. DSR6434 has demonstrated anti-tumor activity in preclinical models, particularly when used in combination with other therapies such as ionizing radiation, leading to enhanced reduction in tumor burden and improved survival in animal models. It has also been evaluated for its ability to stimulate immune cell proliferation and as a candidate for local delivery via drug-eluting embolic microspheres. DSR6434 is notable for its high potency (EC50 ≈ 7.2 nM) and improved water solubility compared to other TLR7 agonists. Its development has primarily focused on cancer immunotherapy, with additional interest in infectious diseases such as chronic hepatitis B viral infection[3][7][8][1][2][4][5][6].

Other names

DSR6434DSR-6434DSR 6434